Although MRT-92 appears a promising candidate for future clinical studies, interference with SMO alone may not be effective in blocking HH signaling in cancers having canonical and non-canonical HH/GLI signaling activation, such as melanoma. The gene discussed is SMO; the disease is melanoma.